SHANGHAI – Starting out with a bang, newly formed biopharma Cstone Pharmaceuticals Co. Ltd. has filed an investigative new drug application with the Jiangsu FDA for its recombinant anti-PD-L1 monoclonal antibody (WBP3155). The firm now awaits approval from the regulators before it can study the PD-L1 antibody in Chinese patients. Read More

PERTH, Australia – A number of initiatives over the last decade have helped to stimulate research and development in Australia, and the country does pretty well globally as far as its mix of intellectual property and research and development. Read More

PERTH, Australia – With only a handful of venture capital firms investing in the life sciences in Australia, the industry has had to look largely to the government for support. Read More

HONG KONG – Scientists in Japan have identified an essential amino acid that is vital for the maintenance of hematopoietic stem cells (HSCs) in mice. That is a key finding that may lead to the development of a safer, more targeted pre-treatment regimen for bone marrow transplantation (BMT) in humans and possibly even a new approach to cancer therapy. Read More

HONG KONG – While prominent household names like Hanmi Pharmaceutical Co. Ltd, Celltrion Inc. and Samsung Biologics Co. Ltd. seem to be hogging the global stage, inking large numbers of out-licensing deals worth billions, lesser-known South Korean drugmakers are also looking outward – just not in the same direction. Read More

Oncolys Biopharma Inc., of Tokyo, entered a joint research agreement with DNA Chip Research Inc., also of Tokyo, to study the potential of Telomescan as a companion diagnostic drug for castration-resistant prostate cancer (CRPC). Read More